An observational study in Neonatal Respiratory Distress, sponsored by University of Stellenbosch. Recruiting at 1 site in South Africa. Open to participants aged 26 Weeks to 32 Weeks. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by University of Stellenbosch · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will look at whether a monitoring method called near-infrared spectroscopy (NIRS), can help assess lung disease in premature babies.
The main aim of this study is to describe lung oxygen levels measured by NIRS in premature babies with respiratory distress syndrome (RDS) during the first 72 hours after birth. The study will include babies born at or before 32 weeks of pregnancy who need continuous positive airway pressure (CPAP) for RDS. The study will also assess whether these lung oxygen measurements can help predict which babies will need surfactant treatment, and whether they can predict which babies may need more than one dose of surfactant.
The study will also compare lung NIRS measurements with other ways of assessing breathing problems, including lung ultrasound scores and oxygen-related measurements. In addition, the researchers will compare lung oxygen measurements with brain oxygen measurements. They will also look at whether surfactant treatment changes oxygen levels in the lungs and brain. Information from routine vital signs, such as heart rate, breathing rate, and oxygen saturation, will also be studied to see whether these measurements can help predict the need for surfactant.
Added to this researchers will look at the hemodynamics of surfactant administration by seeing how the heart and blood vessels react to surfactant administration
Aim: To determine pulmonary regional oxygen saturation (prSO2) in preterm infants (≤32 weeks) with respiratory distress syndrome (RDS) requiring continuous positive airway pressure (CPAP) with or without surfactant replacement therapy (SRT)
Objectives:
Primary: Determine longitudinal prSO2 values for infants with RDS during first 72 hours of life. Secondary: (1) Evaluate the ability of prSO2 to predict the need for surfactant administration in preterm infants with RDS, (2) Evaluate the ability of prSO2 to predict the need for repeat surfactant administration in preterm infants with RDS, (3) Determine correlation between prSO2, lung ultrasound (LUS) scores and oxygenation indices.
Tertiary: (1) Determine the correlation between prSO2 and cerebral oxygenation (crSO2), (2) Determine the effect of surfactant administration on prSO2 and crSO2, (3) longitudinal analyses of vital signs (HR, SpO2, NIRS, oxygenation indices) to predict SRT, (4) determine the hemodynamic effects of SRT (longitudinal correlation of NIRS, haemodynamic parameters)
This will be an investigator-initiated, prospective, observational trial.
Preterm infants born at a gestational age ≤ 32 weeks will be recruited from a single neonatal center, Tygerberg Hospital, Cape Town, South Africa.
All preterm infants ≤ 32 weeks and/ or ≤1800g will be eligible for enrollment
Study Procedures
Recruitment and enrollment processes Infants will be screened within the first 3 hours after birth. Infants meeting enrollment criteria will be placed on study monitoring devices upon arrival in the neonatal unit, if meeting eligibility criteria.
Randomization/ blinding No randomization will occur in this study. Blinding is not possible due to visible monitoring equipment. Treating clinicians will however be directed not to use the monitors for any decision-making regarding patient management.
Monitoring Devices
Near-infrared spectroscopy will be performed using INVOS 5100c (Medtronics, Minneapolis, MN, USA) with 2 transducers, will be used that allows monitoring of 4 regions of interest. In this study 3 regional saturations will be monitored - pulmonary (left and right) and cerebral
Intervention procedures
1. Ultrasound:
Trial duration
The trial will start enrolling 1 November 2026 or when all procedures have been completed. Trial will be completed when 100 participants have been recruited.
Discontinuation of study intervention
Monitoring of the infant will stop, and sensors will be removed if:
Withdrawal from study
At any time point the mother or treating clinician may request withdrawal of the infant from the study, for any reason, whether for personal choice (by the mother), safety considerations or administrative reasons. Monitoring of the infant will be stopped immediately, and no further data will be collected. However, the infant will remain in the study for data analyses and outcome and clinical measure collection, unless the mother specifically requests that their infant's data not be included. Withdrawal of the infant from the study, irrespective of reason, will not influence the continued management of the infant and they will continue to receive management as per protocols in the institution.
Duration of study participation
Study participation for each infant is:
Infants who are transferred to other institutions will be followed up for length of stay as well as neonatal respiratory complications (length of respiratory support, bronchopulmonary dysplasia, death)
378 studies on the registry are indexed under Pulmonary Atelectasis; 91 are open to participants now.
This study's planned enrollment of 100 is above the median of 78 across 101 observational studies indexed under Pulmonary Atelectasis.
Browse Pulmonary Atelectasis studies →University of Stellenbosch is the lead sponsor of 35 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
All preterm infants 27-32 weeks born at Tygerberg Hospital, Cape Town, South Africa will be elligible for enrollment
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Infants receiving CPAP only
Device: Pulmonary near-infra-red spectroscopy
Infants receiving CPAP plus surfactant
Device: Pulmonary near-infra-red spectroscopy
Pulmonary near-infrared spectroscopy sensors will be placed in a horizontal position
PRSO2 values
Determine longitudinal prSO2 values for infants with RDS during first 72 hours of life
Time frame: 72 hours
SRT prediction
Evaluate the ability of prSO2 to predict the need for surfactant administration in preterm infants with RDS
Time frame: 72 hours
Compare prSo2 & lung ultrasound between groups
Determine correlation between prSO2 and lung ultrasound (LUS) scores between groups
Time frame: 72 hours
Compare prSo2 & OSI between groups
Determine correlation between prSO2 and OSI between groups
Time frame: 72 hours
Compare prSo2 & SOPI between groups
Determine correlation between prSO2 and SOPI between groups
Time frame: 72hrs
PRSO2/CUS
Determine the correlation between prSO2 and cerebral oxygenation (crSO2) between groups
Time frame: 72hours
Longitudinal analysis SOPI
longitudinal comparison of SOPI between groups
Time frame: 72 hours
Longitudinal OSI
longitudinal comparison of OSI between groups
Time frame: 72 hours
Longitudinal thoracic fluid content (TFC)
longitudinal comparison of TFC between groups
Time frame: 72 hours
Longitudinal CI
longitudinal comparison of cardiac index between groups
Time frame: 72 hours
Plan to share: No — Patient data, as per SUN HREC guidelines, can only be shared upon an agreed upon data sharing agreement
Start is estimated for Dec 2026; primary completion for Dec 2027, 12 months later.
Of 58 non-industry observational studies under Pulmonary Atelectasis, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 19. This study's planned 12 months is close to that.
Counting every sponsor, half of 58 studies reached it within 11 months; a quarter within 6 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Stellenbosch